[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591565":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":18,"locations":25,"responsibleParty":44,"collaborators":18,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":18,"eligibilityCriteria":51,"healthyVolunteers":48,"sex":52,"minAge":53,"maxAge":18,"enrollmentInfo":54,"targetDuration":18,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":18,"overallStatus":28,"whyStopped":18,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Ain Shams University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dapagliflozin","EXPERIMENTAL","Eligible patients will receive dapagliflozin 10 mg in addition to standard of care",[13],"Drug: Dapagliflozin 10 mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Control arm","NO_INTERVENTION","Eligible patients will receive standard of care only",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Dapagliflozin 10 mg","Dapagliflozin 10 mg will be added in addition to standard of care",[9],[26],{"facility":27,"status":28,"city":29,"state":18,"zip":18,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Ain Shams University Hospitals","RECRUITING","Cairo","Egypt","EG",{"type":33,"coordinates":34},"Point",[35,36],31.24967,30.06263,{"lat":36,"lon":35},[39],{"name":40,"role":41,"phone":42,"phoneExt":18,"email":43},"Mohamed Ahmed, MSc","CONTACT","+201002831275","mohamed.mohyeldin@med.asu.edu.eg",{"type":45,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100591565","phase-3-effects-of-sodium-glucose-cotransporter-2-inhibitors-on-kidney-function-in-advanced-chronic-kidney-disease-100591565",false,"NCT06982079","Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease","Inclusion Criteria:\n\n* Adult patients aged eighteen or older.\n* Patients with advanced chronic kidney disease (i.e., eGFR \\\u003C 20 mL\u002Fmin\u002F1.73m2)not on dialysis\n\nExclusion Criteria:\n\n* Autosomal dominant polycystic kidney disease (ADPKD).\n* Type 1 diabetes mellitus\n* Patients on SGLT2 inhibitors.\n* History of ketoacidosis in the last 3 months.\n* Known hypersensitivity to SGLT2 inhibitors.\n* Known hepatic impairment.\n* Pregnant or breastfeeding females.","ALL","18 Years",{"count":55,"type":56},60,"ESTIMATED","INTERVENTIONAL",[59],"PHASE3","The goal of this clinical trial is to evaluate whether dapagliflozin can reduce the risk of worsening kidney function or death from cardiovascular or renal causes in adults with advanced chronic kidney disease (CKD), with or without type 2 diabetes. The main questions it aims to answer are:\n\n1. Does dapagliflozin reduce the rate of decline in kidney function or progression to end-stage kidney disease in adults with advanced CKD?\n2. Does dapagliflozin reduce the risk of death from cardiovascular or renal causes in patients with advanced CKD?\n\nResearchers will compare dapagliflozin to a placebo to see if dapagliflozin improves kidney and cardiovascular outcomes in this high-risk population.",[62,63],"Chronic Kidney Disease Stage 5","CKD Stage 4","2025-05-19",{"date":66,"type":67},"2025-05-21","ACTUAL",{"date":69,"type":67},"2025-05-01",{"date":71,"type":56},"2026-11-01",{"name":5,"class":6},1]